Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Smith

Showing results (251-260 of 303) with videos related to

Pageof 31
Sort By:
Arthritis Care & Research|September 20, 2014
2013 American College of Rheumatology/European League against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research GroupHebah Alhajeri, Marie Hudson, Marvin Fritzler, et al.
The Journal of Rheumatology|September 17, 2018
Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus ErythematosusChristine A Peschken, Yishu Wang, Michal Abrahamowicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2024
Project Confirm: Accelerated Drug Approvals for CML-ResponseKendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 19, 2007
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Leukemia Research|September 26, 2021
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemiaHetty E Carraway, Yazeed Sawalha, Ivana Gojo, et al.
Leukemia Research|August 18, 2018
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)Joshua F Zeidner, Matthew C Foster, Amanda L Blackford, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 1, 2005
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 13, 2006
Acute myeloid leukemia clinical practice guidelines in oncologyMargaret R O'Donnell, Frederick R Appelbaum, Maria R Baer, et al.
Haematologica|May 30, 2015
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemiaJoshua F Zeidner, Matthew C Foster, Amanda L Blackford, et al.
Blood|November 15, 2011
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignanciesMamta Gupta, Andrea E Wahner Hendrickson, Seong Seok Yun, et al.
Pageof 31

Showing results (251-260 of 303) with videos related to

Sort By:
Pageof 31
Arthritis Care & Research|September 20, 2014
2013 American College of Rheumatology/European League against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research GroupHebah Alhajeri, Marie Hudson, Marvin Fritzler, et al.
The Journal of Rheumatology|September 17, 2018
Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus ErythematosusChristine A Peschken, Yishu Wang, Michal Abrahamowicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2024
Project Confirm: Accelerated Drug Approvals for CML-ResponseKendra L Sweet, Jorge E Cortes, Jane F Apperley, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 19, 2007
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Leukemia Research|September 26, 2021
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemiaHetty E Carraway, Yazeed Sawalha, Ivana Gojo, et al.
Leukemia Research|August 18, 2018
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)Joshua F Zeidner, Matthew C Foster, Amanda L Blackford, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 1, 2005
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 13, 2006
Acute myeloid leukemia clinical practice guidelines in oncologyMargaret R O'Donnell, Frederick R Appelbaum, Maria R Baer, et al.
Haematologica|May 30, 2015
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemiaJoshua F Zeidner, Matthew C Foster, Amanda L Blackford, et al.
Blood|November 15, 2011
Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignanciesMamta Gupta, Andrea E Wahner Hendrickson, Seong Seok Yun, et al.
Pageof 31